2001
DOI: 10.1161/hh2401.101272
|View full text |Cite
|
Sign up to set email alerts
|

CD40 Signaling and Plaque Instability

Abstract: Abstract-Today, multiple lines of evidence support the view of atherosclerosis as a chronic inflammatory disease and implicate components of the immune system in atherogenesis. Recent work has documented overexpression of the potent immune mediator CD40 and its counterpart CD40 ligand (CD40L) in experimental and human atherosclerotic lesions. Notably, interruption of CD40/CD40L interactions not only diminished the formation and progression of mouse atheroma, but also fostered changes in lesion biology and stru… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

13
403
1
13

Year Published

2003
2003
2012
2012

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 506 publications
(430 citation statements)
references
References 142 publications
13
403
1
13
Order By: Relevance
“…[1][2][3] CD40 and CD40L are expressed on endothelial cells, vascular smooth muscle cells, mononuclear cells, and platelets, and CD40-CD40L interaction has been shown to exhibit proinflammatory and proatherogenic effects in vitro and in vivo. 4,5 In addition to the cell-associated form, CD40L also exists in a soluble, biologically active form (sCD40L), which has similar proinflammatory effects on vascular cells.…”
Section: Nteraction Of the Multipotent Immunomodulator Cd40mentioning
confidence: 99%
“…[1][2][3] CD40 and CD40L are expressed on endothelial cells, vascular smooth muscle cells, mononuclear cells, and platelets, and CD40-CD40L interaction has been shown to exhibit proinflammatory and proatherogenic effects in vitro and in vivo. 4,5 In addition to the cell-associated form, CD40L also exists in a soluble, biologically active form (sCD40L), which has similar proinflammatory effects on vascular cells.…”
Section: Nteraction Of the Multipotent Immunomodulator Cd40mentioning
confidence: 99%
“…While extensive research is dedicated to the effect of an inflammatory reaction on obesity-related insulin resistance, little is known about the triggering pathway of inflammation during obesity. Considerable evidence implicates the proinflammatory CD40 molecule, TNF receptor superfamily member 5 (CD40) ligand (CD40L or CD154) in atherosclerosis [2][3][4], and some recent data identify CD40/CD40L as a potential contributor to inflammation associated with obesity and its metabolic complications. Soluble CD40L (sCD40L) levels are increased in obese [5,6] and type 2 diabetic [7][8][9] individuals, as well as in individuals with the metabolic (insulin resistance) syndrome [10].…”
Section: Introductionmentioning
confidence: 99%
“…10 Conversely, there is potential for therapeutic activity by CD40 blockade, which might be beneficial in the treatment of chronic inflammatory diseases, such as multiple sclerosis, systemic lupus erythematosus, spontaneous autoimmune diabetes and atherosclerosis, as well as providing a mechanism for maintaining peripheral tolerance following allograft transplantation. [11][12][13] In contrast to CD40, CD40L is primarily expressed by activated CD4 þ T lymphocytes, but it is also present in mast cells, basophils, and platelets. 4 High levels of CD40L expression on a per cell basis are critical for receptor clustering and consequently CD40 signaling.…”
mentioning
confidence: 99%